Daratumumab is a humanized, antiCD38 IgG1 monoclonal antibody that binds to CD38 expressed by tumor cells through complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), and antibody-dependent phagocytosis (ADCP), as well as Fcγ receptors and other immune-related mechanisms, to induce tumor cell apoptosis [10]. The gene discussed is CD38; the disease is neoplasm.